SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
The present disclosure relates to the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are splice switch oligonucleotide (SSO) molecules for targeting β-catenin, compositions containing the same, and uses thereof for treating or preventing β-catenin associated diseases or disorders. In particular, the present invention is in the field of SSO molecules that targets β-catenin for treatment of cancer..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 03. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
HONG JIN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-08-03, Last update posted on www.tib.eu: 2023-08-22, Last updated: 2023-08-29 |
|---|
| Patentnummer: |
WO2023122316 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017612160 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017612160 | ||
| 003 | DE-627 | ||
| 005 | 20230829134314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017612160 | ||
| 035 | |a (EPA)WO2023122316 | ||
| 035 | |a (EPA)85172415 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a HONG JIN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-08-03, Last update posted on www.tib.eu: 2023-08-22, Last updated: 2023-08-29 | ||
| 520 | |a The present disclosure relates to the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are splice switch oligonucleotide (SSO) molecules for targeting β-catenin, compositions containing the same, and uses thereof for treating or preventing β-catenin associated diseases or disorders. In particular, the present invention is in the field of SSO molecules that targets β-catenin for treatment of cancer. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a BEIGELMAN LEONID |4 aut | |
| 700 | 0 | |a BHATTACHARYA ANEERBAN |4 aut | |
| 700 | 0 | |a ELTEPU LAXMAN |4 aut | |
| 700 | 0 | |a HUANG VERA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 03. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:03 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/85172415/publication/WO2023122316A1?q=WO2023122316 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 03 |c 08 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 03 |c 08 | ||